Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
14.93
+0.83 (5.89%)
At close: May 12, 2025, 4:00 PM
15.40
+0.47 (3.15%)
After-hours: May 12, 2025, 7:12 PM EDT
Spyre Therapeutics Employees
Spyre Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 35 or 116.67% compared to the previous year.
Employees
65
Change (1Y)
35
Growth (1Y)
116.67%
Revenue / Employee
n/a
Profits / Employee
-$2,449,785
Market Cap
901.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SYRE News
- 4 days ago - Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 days ago - Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PRNewsWire
- 10 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 6 weeks ago - Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PRNewsWire
- 2 months ago - Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
- 2 months ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PRNewsWire
- 2 months ago - Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation - PRNewsWire